What question did this study set out to answer?

To evaluate the clinical significance and spatial distribution of stromal CXCL12 expression at the invasive front of pancreatic ductal adenocarcinoma.

August 1, 2026Clinical Medicine Insights OncologyOpen Access

CXCL12 Expression and Clinicopathological Features at the Invasive Front of Pancreatic Cancer

View Full Paper

Ask AI

Bookmark

Authors

SIShunsuke Imamura TUTakeshi Uehara MIMai Iwaya

Discussion

Member takes

Overview

Retrospective study reveals stromal CXCL12 correlates with reduced venous invasion in pancreatic ductal adenocarcinoma, suggesting its potential role as a favorable prognostic biomarker.

Key Points

To evaluate the clinical significance and spatial distribution of stromal CXCL12 expression at the invasive front of pancreatic ductal adenocarcinoma.
Retrospective analysis of CXCL12 expression using RNAscope in situ hybridization in 66 pancreatic ductal adenocarcinoma tissue samples infiltrating peripancreatic fat.
Categorized RNA expression into high and low groups to assess associations with clinicopathological characteristics and patient survival outcomes.
Single-cell RNA sequencing (scRNA-seq) performed to identify the cellular sources of CXCL12 and its receptor CXCR4.
CXCL12-positive staining was observed in 88% of samples, localized predominantly to stromal fibroblasts and endothelial cells, while CXCR4 was expressed mainly on immune cells (T cells, B cells, and myeloid cells).
High CXCL12 expression was significantly associated with lower rates of venous invasion compared to low expression (P = 0.019).
Overall survival did not differ significantly between high and low CXCL12 groups (P = 0.233), but relapse-free survival trended toward being longer in the high CXCL12 group (P = 0.0673).

Cite This Study

Imamura et al. (2026) studied this question.

synapsesocial.com/papers/6a8505e65c0b46d4e29911e8 https://doi.org/10.1177/11795549261473797

View Full Paper

Ask AI

Bookmark

August 1, 2026Clinical Medicine Insights OncologyOpen Access

CXCL12 Expression and Clinicopathological Features at the Invasive Front of Pancreatic Cancer

View Full Paper

Ask AI

Bookmark

Authors

SIShunsuke Imamura TUTakeshi Uehara MIMai Iwaya

Discussion

Member takes

Overview

Retrospective study reveals stromal CXCL12 correlates with reduced venous invasion in pancreatic ductal adenocarcinoma, suggesting its potential role as a favorable prognostic biomarker.

Key Points

To evaluate the clinical significance and spatial distribution of stromal CXCL12 expression at the invasive front of pancreatic ductal adenocarcinoma.
Retrospective analysis of CXCL12 expression using RNAscope in situ hybridization in 66 pancreatic ductal adenocarcinoma tissue samples infiltrating peripancreatic fat.
Categorized RNA expression into high and low groups to assess associations with clinicopathological characteristics and patient survival outcomes.
Single-cell RNA sequencing (scRNA-seq) performed to identify the cellular sources of CXCL12 and its receptor CXCR4.
CXCL12-positive staining was observed in 88% of samples, localized predominantly to stromal fibroblasts and endothelial cells, while CXCR4 was expressed mainly on immune cells (T cells, B cells, and myeloid cells).
High CXCL12 expression was significantly associated with lower rates of venous invasion compared to low expression (P = 0.019).
Overall survival did not differ significantly between high and low CXCL12 groups (P = 0.233), but relapse-free survival trended toward being longer in the high CXCL12 group (P = 0.0673).

Cite This Study

Imamura et al. (2026) studied this question.

synapsesocial.com/papers/6a8505e65c0b46d4e29911e8 https://doi.org/10.1177/11795549261473797

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark